Panitumumab plus trifluridine/tipiracil as anti‐ EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial
International Journal of Cancer · 2023
DOI: 10.1002/ijc.34632 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Cancer, 2023. Verfasst von Stefania Napolitano und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Precision Medicine, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Regione Campania.
Abstract (Originalsprache)
The randomized phase II VELO trial showed that the addition of panitumumab to trifluridine/tipiracil significantly improves progression‐free survival (PFS) as compared to trifluridine/tipiracil in third‐line therapy in patients with refractory RAS wild‐type (WT) metastatic colorectal cancer (mCRC). With longer follow‐up, final overall survival results and posttreatment subgroup analysis are presented. Sixty‐two patients with refractory RAS WT mCRC were randomly assigned to receive, as third‐line therapy, trifluridine/tipiracil alone (arm A) or in combination with panitumumab (arm B). Primary endpoint was PFS; secondary endpoints included overall survival (OS) and overall response rate (ORR). Median OS was 13.1 months (95% CI 9.5‐16.7) in arm A compared to 11.6 months (95% CI 6.3‐17.0) in arm B (HR: 0.96, 95% CI 0.54‐1.71, P = .9). To evaluate the impact of subsequent lines of treatment, subgroup analysis was performed for the 24/30 patients in arm A, that received fourth‐line therapy after disease progression. Median PFS was 4.1 months (95% CI 1.44‐6.83) for 17 patients treated with anti‐EGFR rechallenge as compared to 3.0 months (95% CI 1.61‐4.31) for seven patients that received other therapies (HR: 0.29, 95% CI 0.10‐0.85, P = .024). Median OS from the start of fourth‐line treatment was 13.6 months (95% CI 7.2‐20), and 5.1 months (95% CI 1.8‐8.3) for patients treated with anti‐EGFR rechallenge vs other therapies, respectively (HR: 0.30, 95% CI 0.11‐0.81, P = .019). Final results of the VELO trial support the role of anti‐EGFR rechallenge in the continuum of care of patients with RAS/BRAF WT mCRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Precision Medicine, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy.
- Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milan, Italy.
- Oncologia Medica, Istituto Nazionale per lo Studio e la Cura dei Tumori "Fondazione Giovanni Pascale" - IRCCS, Naples, Italy.
- UOC Oncologia, A.O.R.N. dei Colli (Monaldi-Cotugno-CTO), Naples, Italy.
- Department of Oncology, University of Turin at Ordine Mauriziano Hospital, Turin, Italy.
ORCID-Profile: Davide Ciardiello, Vincenzo De Falco, Giulia Martini
Förderung
- Regione Campania
Zitieren
APA
Napolitano, S., Ciardiello, D., De Falco, V., Martini, G., Martinelli, E., Della Corte, C. M., Esposito, L., Famiglietti, V., Di Liello, A., Avallone, A., Cardone, C., De Stefano, A., Montesarchio, V., Zampino, M. G., Fazio, N., Di Maio, M., Del Tufo, S., De Vita, F., Altucci, L., …, & Troiani, T. (2023). Panitumumab plus trifluridine/tipiracil as anti‐ EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial. International Journal of Cancer. https://doi.org/10.1002/ijc.34632
Vancouver
Napolitano S, Ciardiello D, De Falco V, Martini G, Martinelli E, Della Corte CM, et al. Panitumumab plus trifluridine/tipiracil as anti‐ EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial. International Journal of Cancer. 2023. doi:10.1002/ijc.34632
BibTeX
@article{Napolitano2023,
author = {Napolitano, Stefania and Ciardiello, Davide and De Falco, Vincenzo and Martini, Giulia and Martinelli, Erika and Della Corte, Carminia Maria and Esposito, Lucia and Famiglietti, Vincenzo and Di Liello, Alessandra and Avallone, Antonio and Cardone, Claudia and De Stefano, Alfonso and Montesarchio, Vincenzo and Zampino, Maria Giulia and Fazio, Nicola and Di Maio, Massimo and Del Tufo, Sara and De Vita, Ferdinando and Altucci, Lucia and Marrone, Francesca and Ciardiello, Fortunato and Troiani, Teresa},
title = {Panitumumab plus trifluridine/tipiracil as anti‐ EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial},
journal = {International Journal of Cancer},
year = {2023},
doi = {10.1002/ijc.34632}
}
EUVIMED